However, not every patient responds identically to either compound, which is why genetic variation in GIPR, and other peptide-pathway genes influences individual treatment outcomes
Laboratory parameters included complete blood count, fasting plasma glucose, C-peptide, HbA1c, AST, ALT, -GTP, amylase, lipase, uric acid, BUN, creatinine, total cholesterol, HDL-cholesterol, and triglycerides
Forward-Looking Statements This press release contains forward-looking statements that are based on the current beliefs and expectations of Daewoong Pharmaceutical's management
In combination with metformin immediate-release and rosiglitazone, sitagliptin provided significant improvements in A1C, FPG, and 2-hour PPG compared to placebo with metformin immediate-release and rosiglitazone (Table 12) at Week 18